Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

2.76USD
28 Sep 2016
Change (% chg)

-- (--)
Prev Close
$2.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
461,133
52-wk High
$14.20
52-wk Low
$2.54

Select another date:

Thu, Aug 25 2016

BRIEF-Immunogen announces update to financial results year ended June 30, 2016 - SEC filing

* Announces update to financial results for the quarter and year ended June 30, 2016 - SEC filing

BRIEF-Immunogen reports departure of chief development officer

* Immunogen announces departure of chief development officer Source text for Eikon: Further company coverage:

BRIEF-Immunogen Q4 loss per share $0.51

* Immunogen reports fourth quarter and fiscal year 2016 financial results and provides quarterly business update

BRIEF-ImmunoGen announces pricing of $100 mln offering of Senior Notes

* Sale of notes is expected to result in $96.7 million net proceeds to Immunogen

BRIEF-Immunogen announces proposed $100 mln offering of convertible senior notes

* Immunogen announces proposed $100 million offering of convertible senior notes due 2021

BRIEF-ImmunoGen reports positive early-stage data on ovarian cancer drug

* Reports efficacy and safety data from a 46 patient cohort of mirvetuximab soravtansine in fr-positive ovarian cancer

BRIEF-ImmunoGen Inc Q3 loss per share $0.37

* Immunogen Inc reports third quarter fiscal year 2016 financial results and provides corporate update

BRIEF-Immunogen appoints Mark Enyedy to newly-expanded board

* Board has voted to expand size of board from nine to ten members, and appointed Mark Enyedy to fill newly-created vacancy - SEC filing Source text for Eikon: [(http://1.usa.gov/1SHhbkP )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-ImmunoGen appoints Mark Enyedy as president and CEO

* Immunogen appoints Mark Enyedy as president and chief executive officer

Select another date: